Introduction
VEGFA (VEGF), VEGFB, VEGFC, VEGFD (FIGF) and PGF (PlGF) are VEGF family proteins implicated in vascular remodeling during embryogenesis, tissue regeneration, and carcinogenesis (1) (2) (3) (4) . VEGF family members are ligands for receptor tyrosine kinases, including VEGFR1 (FLT1), VEGFR2 (KDR) and VEGFR3 (FLT4). Bevacizumab (Avastin) is a humanized anti-VEGFA monoclonal antibody, while Sunitinib (Sutent) and Sorafenib (Nexavar) are multikinase inhibitors for VEGFR1 and other protein kinases. Bevacizumab, Sunitinib and Sorafenib are anti-cancer drugs targeted to VEGF signaling pathway (5) (6) (7) (8) .
VEGF-induced expression of DLL4 in vascular endothelial cells leads to the activation of Notch signaling, and the following down-regulation of HHIP1 (9-11). HHIP1 downregulation then leads to SHH activation, which results in the activation of VEGF signaling. Therefore, VEGF-induced down-regulation of HHIP1 during angiogenesis leads to the positive feedback to the Hedgehog-VEGF-Notch signaling cascade (11) . VEGF, Hedgehog, FGF, Notch, and WNT signaling pathways network together for vascular remodeling during embryogenesis, tissue regeneration, and carcinogenesis (9) (10) (11) (12) (13) (14) (15) (16) (17) .
Canonical WNT signals are transduced to the transcriptional complex consisting of TCF/LEF, ß-catenin, BCL9/BCL9L and PYGO1/PYGO2 to activate transcription of target genes, such as DKK1, DKK4, FGF18 and FGF20 (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) .
TCF/LEF binding sites within the promoter region of human VEGF family members were searched for by using bioinformatics and human intelligence (Humint). Because four TCF/ LEF-binding sites were identified within human VEGFD promoter, comparative genomics analyses on VEGFD orthologs were further performed.
Materials and methods
Screening of WNT target gene. Genome sequences corresponding to human VEGFA, VEGFB, VEGFC, VEGFD and PGF genes were searched for with BLAST programs (http://www.ncbi.nlm.nih.gov) as described previously (29) (30) (31) (32) . TCF/LEF-binding sites within the 5'-flanking promoter region of the above genes were searched for based on bioinformatics and manual inspection as described previously (23) (24) (25) (26) (27) 33) .
Identification of chimpanzee and cow VEGFD orthologs.
Chimpanzee and cow genome sequences homologous to human VEGFD were searched for with BLAST programs as described previously (34) (35) (36) (37) . TCF/LEF-binding sites within the 5'-flanking promoter region of VEGFD orthologs were also searched for.
Comparative integromics analyses. Phylogenetic analyses on VEGF family proteins as well as on promoters of mammalian VEGFD orthologs were performed by using the CLUSTALW program. Human and chimpanzee VEGFD promoters were then aligned by using Genetyx program and manual curation as described previously (38) (39) (40) (41) .
In silico expression analyses. Expressed sequence tags (ESTs) derived from human VEGFD and mouse Vegfd genes were searched for by using the BLAST programs. The sources of human VEGFD ESTs and those of mouse Vegfd ESTs were listed up for in silico expression analyses. (Fig. 1A) . TCF/LEF-binding sites within the 5'-promoter region of human VEGF family genes were then searched for based on manual inspection. Four TCF/LEF-binding sites were identified within human VEGFD promoter (Fig. 1A) .
Results

Screening of the TCF/LEF-binding
Comparative integromics analyses on VEGFD.
Comparative proteomics analysis was performed at first. Phylogenetic analysis on human and mouse VEGF family members revealed that VEGFD orthologs were relatively well conserved (Fig. 1B) .
Intra-species comparative genomics analysis was next performed. FANCB, MOSPD2, ASB9, ASB11, PIGA, PIR and BMX genes were located around the VEGFD gene, while GPM6A, WDR17, SPAT4, ASB5, SPCS3 and NEIL3 genes were located around the VEGFC gene (Fig. 1C) . Paralogs corresponding to genes around the VEGFD locus were searched for by using the BLAST programs. ASB9 and ASB11 genes, encoding ankyrin repeat and SOCS box-containing proteins, were the paralog of ASB5 gene. These facts indicate that ASB9-ASB11-VEGFD locus at human chromosome Xp22.2 and ASB5-VEGFC locus at human chromosome 4q34 were paralogous regions within the human genome (Fig. 1C) .
Expression profile of human VEGFD and mouse Vegfd mRNAs.
In silico expression analyses were performed to compare the expression profile of human VEGFD and mouse Vegfd mRNAs. Human VEGFD mRNA was expressed in lung, small intestine, uterus, breast, neural tissues, and neuroblastoma. Mouse Vegfd mRNA was expressed in kidney, pregnant oviduct, and neural tissues. Identification of the chimpanzee VEGFD ortholog. BLAST programs using human VEGFD RefSeq revealed that chimpanzee VEGFD gene was located within NW_121675.1 genome sequence (Fig. 2A) . Exon-intron boundaries of chimpanzee VEGFD gene were determined based on the consensus sequence of exon-intron junctions. Chimpanzee VEGFD gene was found consisting of seven exons. Compared with human VEGFD RefSeq, one-base insertion occurred at two positions within the N-terminal coding region of chimpanzee VEGFD gene. Re-sequencing of the genome sequence around exon 1 of chimpanzee VEGFD gene should be done in the future to evaluate whether one-base insertions are real insertions or sequencing errors.
Comparative genomics analyses on VEGFD promoters.
Human and chimpanzee VEGFD promoters were located within AC095351.5 and NW_121675.1 genome sequences, respectively, as mentioned above. BLAST programs next revealed that cow, mouse and rat Vegfd promoters were located within AC161065.2, AL732475.6 and AC130036.3 genome sequences, respectively (Fig. 2A) . GC content of human, chimpanzee, cow, mouse and rat VEGFD promoters were 36.3%, 35.5%, 37.4%, 37.3% and 38.2%, respectively. Phylogenetic analysis revealed that human, chimpanzee and cow VEGFD promoters were significantly divergent from mouse and rat Vegfd promoters (Fig. 2B) .
Four TCF/LEF-binding sites within human VEGFD promoter were located about 1300, 1000, 600, and 100 bp upstream of the transcription start site (Fig. 2C) . Three out of four TCF/LEF-binding sites within human VEGFD promoter were conserved in chimpanzee VEGFD promoter, and one in cow Vegfd promoter. TCF/LEF-binding site, not conserved in the human VEGFD promoter, occurred in cow, mouse and rat Vegfd promoters (Fig. 2C) . Although human and chimpanzee VEGFD promoters were well conserved, most proximal TCF/LEF-binding site within human VEGFD promoter was disrupted in chimpanzee VEGFD promoter due to a single nucleotide substitution (Fig. 3) .
Six bHLH-binding sites were clustered within the proximal region of human VEGFD promoter (Fig. 3) . At least five out of six bHLH-binding sites were conserved in chimpanzee VEGFD proximal promoter region, while only one in cow Vegfd proximal promoter region.
Discussion
TCF/LEF binding sites within the promoter region of human VEGFA, VEGFB, VEGFC, VEGFD and PGF genes were searched for in this study. Because four TCF/LEF-binding sites were identified within the 5'-promoter region of human VEGFD gene (Fig. 1A) , comparative genomics analyses on VEGFD orthologs were further performed. ASB9-ASB11-PIGA-VEGFD locus at human chromosome Xp22.2 and ASB5-SPCS3-VEGFC locus at human chromosome 4q34 were paralogous regions within the human genome (Fig. 1C) .
Chimpanzee VEGFD promoter, cow Vegfd promoter, mouse Vegfd promoter and rat Vegfd promoter were identified within NW_121675.1, AC161065.2, AL732475.6 and AC130036.3 genome sequences, respectively ( Fig. 2A) . Three out of four TCF/LEF-binding sites within human VEGFD promoter were conserved in chimpanzee VEGFD promoter, and one in cow Vegfd promoter. TCF/LEF-binding site, not conserved in the human VEGFD promoter, occurred in cow, mouse and rat Vegfd promoters (Fig. 2C) . At least five out of six bHLH-binding sites within human VEGFD proximal promoter region were conserved in chimpanzee VEGFD proximal promoter region, while only one in cow Vegfd proximal promoter region. Together these facts indicate that relatively significant promoter evolution occurred among mammalian VEGFD orthologs.
Human VEGFD was identified as the target gene of WNT/ ß-catenin signaling pathway in this study. Human VEGFD mRNA was expressed in lung, small intestine, uterus, breast, neural tissues, and neuroblastoma. VEGFD, implicated in angiogenesis and lymphatic metastasis, is a pharmacogenomics target in the field of oncology.
